| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
264,900,000 |
| Market
Cap: |
8.27(B) |
| Last
Volume: |
49,305,461 |
Avg
Vol: |
5,854,790 |
| 52
Week Range: |
$4.32 - $31.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 606 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
39,348 |
1,060,446 |
4,785,085 |
4,785,085 |
| Total Sell Value |
$1,152,494 |
$23,992,060 |
$86,338,289 |
$86,338,289 |
| Total People Sold |
4 |
5 |
5 |
5 |
| Total Sell Transactions |
4 |
17 |
26 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wallace Richard John |
|
– • – |
2023-11-07 |
4 |
OE |
$14.70 |
$147,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Lentini Renee |
VP & PRIN ACCTG OFFICER |
• – – |
2023-11-06 |
4 |
S |
$15.29 |
$3,356,843 |
D/D |
(219,545) |
0 |
|
-95% |
|
| Lentini Renee |
VP & PRIN ACCTG OFFICER |
• – – |
2023-11-06 |
4 |
OE |
$2.68 |
$943,442 |
D/D |
120,528 |
219,545 |
|
- |
|
| Goldberg Mark Alan |
|
– • – |
2023-10-30 |
4 |
OE |
$15.08 |
$150,800 |
D/D |
10,000 |
60,151 |
|
- |
|
| Goldberg Mark Alan |
|
– • – |
2023-10-30 |
4 |
OE |
$14.70 |
$147,000 |
D/D |
10,000 |
70,151 |
|
- |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2023-10-16 |
4 |
S |
$14.40 |
$2,764,858 |
D/D |
(192,004) |
2,811 |
|
-113% |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2023-10-16 |
4 |
OE |
$4.55 |
$873,618 |
D/D |
192,004 |
194,815 |
|
- |
|
| Arbuckle Stuart A |
|
– • – |
2023-09-29 |
4 |
A |
$15.87 |
$13,124 |
D/D |
827 |
4,939 |
|
- |
|
| Thackray Helen M. |
|
– • – |
2023-09-29 |
4 |
A |
$15.87 |
$7,491 |
D/D |
472 |
2,822 |
|
- |
|
| Goldberg Mark Alan |
|
– • – |
2023-09-29 |
4 |
A |
$15.87 |
$16,870 |
D/D |
1,063 |
60,151 |
|
- |
|
| Mitchell Dean J |
|
– • – |
2023-09-22 |
4/A |
OE |
$14.70 |
$147,000 |
D/D |
10,000 |
103,000 |
|
- |
|
| Mitchell Dean J |
|
– • – |
2023-09-22 |
4 |
OE |
$14.70 |
$147,000 |
D/D |
10,000 |
152,667 |
|
- |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2023-09-15 |
4 |
S |
$15.44 |
$2,964,681 |
D/D |
(192,013) |
2,811 |
|
-88% |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2023-09-15 |
4 |
OE |
$2.68 |
$397,064 |
D/D |
108,668 |
194,824 |
|
- |
|
| Peterson Kristine |
|
– • – |
2023-09-13 |
4 |
OE |
$16.08 |
$160,800 |
D/D |
10,000 |
0 |
|
- |
|
| Peterson Kristine |
|
– • – |
2023-09-13 |
4 |
OE |
$14.70 |
$147,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Mccluski Stephen C |
|
– • – |
2023-09-13 |
4 |
OE |
$16.05 |
$160,500 |
D/D |
10,000 |
0 |
|
- |
|
| Mccluski Stephen C |
|
– • – |
2023-09-13 |
4 |
OE |
$14.70 |
$147,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Lentini Renee |
PRIN. FIN & ACCTG. OFF. |
• – – |
2023-09-12 |
4 |
OE |
$3.05 |
$99,808 |
D/D |
25,141 |
99,017 |
|
- |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2023-09-08 |
4 |
OE |
$7.69 |
$199,986 |
D/D |
26,006 |
36,966 |
|
- |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2023-08-09 |
4 |
S |
$14.20 |
$1,422,982 |
D/D |
(100,210) |
10,960 |
|
-105% |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2023-08-09 |
4 |
OE |
$4.92 |
$493,033 |
D/D |
100,210 |
111,170 |
|
- |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2023-08-04 |
4 |
S |
$17.05 |
$1,369,558 |
D/D |
(80,326) |
10,960 |
|
-74% |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2023-08-04 |
4 |
OE |
$4.92 |
$395,204 |
D/D |
80,326 |
91,286 |
|
- |
|
| Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-08-04 |
4 |
S |
$16.96 |
$16,831,053 |
D/D |
(992,397) |
553,270 |
|
-74% |
|
257 Records found
|
|
Page 3 of 11 |
|
|
